Neonc Technologies (NTHI) to Release Earnings on Friday

Neonc Technologies (NASDAQ:NTHI) will likely be issuing its results before the market opens on Friday, March 20th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

Neonc Technologies Trading Down 1.2%

Shares of NTHI opened at $8.86 on Wednesday. Neonc Technologies has a 1-year low of $3.20 and a 1-year high of $25.00. The company has a 50-day moving average of $9.44 and a 200 day moving average of $9.42.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Zacks Research raised shares of Neonc Technologies to a “hold” rating in a research note on Wednesday, January 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Neonc Technologies in a research note on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Neonc Technologies has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in shares of Neonc Technologies in the 2nd quarter valued at approximately $801,000. Vanguard Group Inc. purchased a new stake in shares of Neonc Technologies during the 3rd quarter worth $1,279,000. 683 Capital Management LLC purchased a new stake in shares of Neonc Technologies during the 4th quarter worth $442,000. Royal Bank of Canada acquired a new position in shares of Neonc Technologies during the first quarter worth $247,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Neonc Technologies during the fourth quarter worth $126,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.